Actively Recruiting
Personalized ctDNA-Guided Sequential Anti-HER2 Therapy and CNS Prevention for Long-Term Remission in HER2 Metastatic Breast Cancer
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-08-20
60
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a personalized treatment approach for adults with HER2-positive metastatic breast cancer. This study aims to determine if using a series of circulating tumor DNA ctDNA tests alongside standard imaging scans to guide treatment adjustments, combined with local therapies and treatments to prevent cancer spread to the central nervous system brain and spinal cord, can achieve long-lasting remission and possibly cure some participants. Participants receive sequential anti-HER2 therapies including fam-trastuzumab deruxtecan-nxki T-DXd and pertuzumab through intravenous infusions. Diagnostic tests such as Personalis NeXT Personal and Natera Signatera assays are used to optimize treatment decisions without adding significant risks. The study focuses on participants who are medically fit for surgery or potentially operable after induction therapy, with measurable disease and adequate organ function. Throughout the study, participants will be closely monitored using ctDNA tests and imaging scans to guide treatment changes. Researchers will evaluate the proportion of participants maintaining complete response and molecular complete response at 12 months. The study includes safety monitoring and requires participants to provide informed consent, with a total participation period extending up to the studys completion date in 2030.
CONDITIONS
Brief Title
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
Research Team
P
Pedram Razavi, MD, PhD
A
Atif Khan, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here